Figures
Abstract
L265P mutation in the MYD88 gene has recently been reported in Waldenström’s macroglobulinemia; however the incidence has been different according to the methods used. To determine the relevance and compare the incidence by different methods, we analyzed the L265P mutation in bone marrow mononuclear cells from lymphoid neoplasms. We first performed cloning and sequencing in 10 patients: 8 Waldenström’s macroglobulinemia; 1 non-IgM-secreting lymphoplasmacytic lymphoma; and 1 low grade B-cell lymphoma with monoclonal IgG protein. The L265P mutation was detected in only 1/8 Waldenström’s macroglobulinemia patients (2 of 9 clones). To confirm these results, direct sequencing was performed in the 10 patients and an additional 17 Waldenström’s macroglobulinemia patients and 1 lymphoplasmacytic lymphoma patient. Nine of 28 patients (7/25 Waldenström’s macroglobulinemia, 1/2 lymphoplasmacytic lymphoma, and B-cell lymphoma) harbored the mutation. We next tested for the mutation with BSiE1 digestion and allele-specific polymerase chain reaction in the 28 patients and 38 patients with myeloma. Aberrant bands corresponding to the mutation were detected by BSiE1 digestion in 19/25 patients with Waldenström’s macroglobulinemia (76%), 1/2 lymphoplasmacytic lymphoma and B-cell lymphoma, but not in the 38 myeloma patients. The L265P mutation was more frequent in patients with Waldenström’s macroglobulinemia than in those with myeloma (p=1.3x10-10). The mutation was detected by allele-specific polymerase chain reaction in 18/25 Waldenström’s macroglobulinemia patients (72%). In the 25 Waldenström’s macroglobulinemia patients, the L265P was more frequently detected by BSiE1 digestion than by direct sequencing (p=5.3x10-4), and in males (15/16, 94%) than in females (4/9, 44%) (p=1.2x10-2). No siginificant difference was observed in the incidence of the L265P mutation between BSiE1 digestion and allele-specific polymerase chain reaction (p=0.32). These results suggest that the L265P mutation is involved in the majority of Waldenström’s macroglobulinemia. BSiE1 digestion and allele-specific polymerase chain reaction may detect a small fraction of mutated cells in some cases.
Citation: Mori N, Ohwashi M, Yoshinaga K, Mitsuhashi K, Tanaka N, Teramura M, et al. (2013) L265P Mutation of the MYD88 Gene Is Frequent in Waldenström’s Macroglobulinemia and Its Absence in Myeloma. PLoS ONE 8(11): e80088. https://doi.org/10.1371/journal.pone.0080088
Editor: Riccardo Dolcetti, IRCCS National Cancer Institute, Italy
Received: May 13, 2013; Accepted: October 9, 2013; Published: November 5, 2013
Copyright: © 2013 Mori et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: These authors have no support or funding to report.
Competing interests: The authors have declared that no competing interests exist.
Introduction
Waldenström’s macroglobulinemia (WM) is an IgM-secreting-lymphoproliferative neoplasm [1-3]. Monoclonal IgM protein (IgM M-protein) is observed in WM, diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia, monoclonal gammopathy of undetermined significance (MGUS), and autoimmune disease. Pathologically, patients with WM have lymphoplasmacytic lymphoma (LPL); therefore, they can be distinguished from other lymphoma patients with IgM M-protein [2]. Patients with IgM MGUS progress to WM or other B-cell lymphoma. Until recently, molecular findings associated with the disease were not well characterized in WM.
Myeloid differentiation primary response gene 88 (MYD88) is an adaptor protein that mediates toll and interleukin (IL)-1 receptor signaling [4-6]. After the toll-like receptor or IL-1 receptor binds to its ligand, Toll/IL-1 receptor (TIR) domains trigger MYD88 through TIR domain containing adaptor protein and Bruton’s tyrosine kinase or activate MYD88 directly. Subsequently MYD88 dimerizes and induces the phosphorylation of IL-1 receptor-associated kinase (IRAK)4, IRAK1, and IRAK2, leading to inhibitor κBα phosphorylation and the activation of nuclear factor (NF)-κB [7,8]. A recent study using RNA interference screening revealed that MYD88, IRAK1, and IRAK4 were essential for survival of activated B-cell-like subtype of DLBCL cells [9]. Sequencing uncovered that the MYD88 gene was mutated in activated B-cell-like DLBCL tumors [9]. The most frequently found mutation of the MYD88 gene was a T to C transition at nucleotide 978 (T978C mutation, 29%) resulting in a leucine to proline substitution at amino acid position 265 (L265P). This mutation was located in the TIR domain and was rare in other DLBCL subtypes. The L265P mutation triggers IRAK-mediated NF-κB signaling. Other mutations were also found in the TIR domain in the study, but at a lower frequency. Moreover, MYD88 gene mutations were found by whole-exome sequencing in 6 of 55 DLBCL patients (11%) [10]. Somatic mutations of the MYD88 gene were also found in 6 of 46 patients with splenic marginal zone lymphoma (13%) [11]. Non-synonymous MYD88 mutations were observed in 3 of 53 mucosa-associated lymphoid tissue lymphoma patients (6%) [12].
NF-κB signaling is important for the growth and survival of WM cells [13]. The L265P mutation was recently identified in 49 of 54 patients with WM (91%), and 3 of 3 patients with non-IgM-secreting LPL [14]. Inhibition of MYD88 signaling reduced inhibitor κBα and NF-κB p65 phosphorylation, and NF-κB nuclear staining in WM cells expressing MYD88 L265P [14]. Subsequently the mutation was reported to be present in 18 of 27 patients with WM (67%), and was less frequent in marginal zone lymphoma patients [15]. Most recently, the high incidence of the L265P mutation (93-100%) was reported using the sensitive allele-specific polymerase chain reaction (AS-PCR) in WM [16,17]. These findings suggest that the mutation is useful for distinguishing WM from other diseases or conditions with IgM-M protein. However, whether all patients with WM have the mutation, and which methods are suitable for detecting this mutation have yet to be elucidated in detail. To determine the relevance of the L265P mutation and its association with the clinical characteristics of lymphoid neoplasms, we performed sequencing and mutation analysis on the MYD88 gene in WM and B-cell lymphoma patients. The mutation was found in the majority of WM patients, and BSiE1 digestion and AS-PCR were more sensitive than direct sequencing.
Materials and Methods
Patients’ materials
A total of 66 patients with lymphoid neoplasms were analyzed in this study, and consisted of 25 WM, 2 non-IgM-secreting LPL, and 1 low grade B-cell lymphoma with IgG M-protein as well as 38 myeloma (Table 1). Diagnostic criteria by the Second International Workshop on Waldenstrom’s Macroglobulinemia were used in this study [1]. All but one patient had more than 10% bone marrow lymphoplasmacytic infiltration (Table 2). No family history of WM was documented in the patients. Patients with WM1, WM3, WM6, WM7, WM16, and WM25 were administered prednisolone and/or an alkylating agent before bone marrow sampling (Table 2). Mononuclear cells were separated from the bone marrow of hematological neoplasms by Ficoll-Conray gradient centrifugation after obtaining written informed consent. Genomic DNA was prepared by proteinase K digestion and phenol/chloroform extraction or using a QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA, USA). The current study was conducted within the guidelines and with the approval of the Tokyo Women’s Medical University Ethical Committee, and in accordance with the Helsinki Declaration.
| Disease | Number of samples | Number of L265P mutation |
|---|---|---|
| Waldenström’s macroglobulinemia | 25 | 19 |
| non-IgM-secreting lymphoplasmacytic lymphoma | 2 | 1 |
| low grade B-cell lymphoma with IgG M-protein | 1 | 1 |
| 28 | 21 | |
| myeloma | 38 | 0 |
| Total | 66 | 21 |
Table 1. L265P mutation of the MYD88 gene in lymphoid neoplasms.
| Case | Age/sex | Disease | Serum IgM (mg/dl) | Light chain | Lymphocyte in BM (%) | Karyotype | DS | BSiE1 digestion | AS-PCR | Genotype | Allele counts† |
|---|---|---|---|---|---|---|---|---|---|---|---|
| WM1 | 71/Male | WM | 1430 | κ | 29.6 | 46,XY | - | M | M | MW | 1 |
| WM2 | 64/Female | WM | 2302 | λ | 19.0 | NA | - | - | - | WW | 0 |
| WM3 | 41/Female | WM | 2218 | λ | 24.6 | 46,XX | - | - | - | WW | 0 |
| WM4 | 51/Male | WM | 2510 | κ | 21.0 | 46,XY | - | M | M | MW | 1 |
| WM5 | 56/Male | WM | 1996 | κ | 47.4 | 46,XY | M | M | M | MW | 1 |
| WM6 | 74/Female | WM | 1910 | κ | NA | abnormal1* | - | - | - | WW | 0 |
| WM7 | 65/Male | WM | 1095 | λ | 47.4 | 46,XY | M | M | M | MW | 1 |
| WM8 | 82/Male | WM | 2485 | κ | 85.6 | 46,XY | - | M | M | MW | 1 |
| WM9 | 61/Female | WM | 2655 | κ | 43.6 | abnormal2* | M | M | M | MW | 1 |
| WM10 | 68/Male | WM | 2050 | κ | 19.8 | 46,XY | - | M | M | MW | 1 |
| WM11 | 69/Male | WM | 1105 | κ | 44.5 | 46,XY | M | M | M | MW | 1 |
| WM12 | 52/Female | WM | 1264 | λ | 14.4 | NA | - | - | - | WW | 0 |
| WM13 | 72/Male | WM | 2840 | κ | 15.6 | 46,XY | - | M | M | MW | 1 |
| WM14 | 45/Male | WM | 1915 | λ | 14.1 | 46,XY | - | M | M | MW | 1 |
| WM15 | 74/Male | WM | 2578 | κ | 96.4 | 45,X,-Y | M | M | M | MW | 1 |
| WM16 | 78/Female | WM | 1142 | κ | 13.5 | 46,XX | - | M | M | MW | 1 |
| WM17 | 60/Male | WM | 4920 | κ | 49.0 | 46,XY | M | M | M | MW | 1 |
| WM18 | 50/Female | WM | 1728 | λ | 25.0 | 46,XX | - | M | M | MW | 1 |
| WM19 | 76/Male | WM | 2234 | κ | 34.6 | 46,XY | - | M | - | MW | 1 |
| WM20 | 83/Male | WM | 402 | κ | 24.3 | 46,XY | - | - | - | WW | 0 |
| WM21 | 63/Male | WM | 6942 | κ | 91.9 | 46,XY | M | M | M | MW or MM | 1 or 2 |
| WM22 | 77/Male | WM | 2008 | λ | 16.8 | 45,X,-Y | - | M | M | MW | 1 |
| WM23 | 60/Male | WM | 2788 | κ | 43.6 | 46,XY | - | M | M | MW | 1 |
| WM24 | 70/Female | WM | 2065 | κ | 89.5 | 47,XX,+12 | - | - | - | WW | 0 |
| WM25 | 72/Female | WM | 2471 | κ | 17.1 | 46,XX | - | M | M | MW | 1 |
| NHL1 | 45/Male | LPL | 7 | (κ) | 66.7 | abnormal3* | - | - | - | WW | 0 |
| NHL2 | 58/Male | LPL | 12 | (κ) | 17.6 | 46,XY | M | M | M | MW | 1 |
| NHL3 | 64/Female | NHL | 31 | λ | 92.2 | NA | M | M | M | MW | 1 |
Table 2. Clinical characteristics of Waldenström’s macroglobulinemia and lymphoma.
PCR
Sequences of primers for PCR were published previously:
MY-F, 5'-GGGATATGCTGAACTAAGTTGCCAC3'; and
MY-R, 5'-GACGTGTCTGTGAAGTTGGCATCTC-3' [14].
PCR was performed with 10 ng of DNA. After 5 min at 94 °C, 30 cycles of amplification using 60 s at 94 °C, 60 s at 60 °C, and 60 s at 72 °C were performed, with a subsequent 5 min extension at 72 °C. Primers MY-F and MY-R amplified 726 base pairs (bp) products which cover the TIR domain.
Sequencing
PCR products were purified using the QIAQuick PCR Purification Kit (Qiagen) and ligated into the pGEM-T vector (Promega, Madison, WI, USA). After cloning, sequencing was performed in both directions on a MegaBase sequence system (Amersham, Buckingham, UK) [18]. Direct sequencing was also performed using purified PCR products.
BSiE1 restriction enzyme digestion
We tested for the L265P mutation with BSiE1 restriction enzyme digestion (New England Biolabs, Tokyo, Japan) [15]. The 726 bp PCR products were purified, digested with BSiE1, and subjected to electrophoresis through a 2% agarose gel. The presence of both 448 bp and 278 bp products indicated the L265P mutation, while the 726 bp products indicated the wild-type. In each sample, electrophoresis was repeated three to five times using independent PCR products.
AS-PCR
AS-PCR was performed with specific forward primers with a single base substitution at the end of the primer: MYW-F, 5’-GTGCCCATCAGAAGCGCCT-3’ (wild type) and MYM-F, 5’-GTGCCCATCAGAAGCGCCC-3’ (mutant). Allele-specific primers contained an intentional mismatch at the third nucleotide from the 3’ end to improve specificity [17]. The sequence of the reverse primer was the same as that used for sequencing. PCR was performed with 10 ng of DNA. After 5 min at 94 °C, 35 cycles of amplification using 60 s at 94 °C, 60 s at 65 °C, and 60 s at 72 °C were performed, with a subsequent 5 min extension at 72 °C. Primers MYW-F (or MYM-F) and MY-R amplified 224 bp products.
Statistical analysis
Correlations between the frequency of the L265P mutation and type of disease or clinical characteristics were analyzed using the chi-square test or Fisher’s exact probability test. Statistical analysis for the mutation between direct sequencing or AS-PCR and BSiE1 digestion was performed with the Wilcoxon’s signed-ranks test. Correlations between the percentage of lymphocytes and presence of L265P or sex were analyzed using the Mann-Whitney’s U- test. Correlations between the IgM concentration and presence of L265P were analyzed using the Mann-Whitney’s U- test. Statistical analyses were performed using Dr SPSSII (version 11.01) or Statcel 3 software. A P-value of less than 0.05 was considered significant.
Results
Sequencing
We first selected 10 patients including 8 WM (WM1-WM8), 1 non-IgM-secreting LPL (NHL1), and 1 low grade B-cell lymphoma with IgG M-protein (NHL3) for cloning (Table 2). Sequencing was performed using at least four clones in each patient. The nucleotide change, the T to C transition resulting in the L265P mutation, was detected in 2 of 9 clones from 1 patient with WM (WM5), while it was absent in any of the clones from the other 9 patients (Figure 1 A-B). Because of the low frequency of the mutation, we next performed direct sequencing in the 10 patients and an additional 17 patients with WM and 1 LPL patient. The T to C transition was detected in 9 of 28 patients (32%) (Table 2, Figure 1 C). It was found in 7 of the 25 WM patients (28%), one of the 2 LPL, and 1 low grade B-cell lymphoma with IgG M-protein. All of the 9 patients with the transition also had wild-type sequences. To determine sensitivity, DNA from the L265P-positive clone (WM5) was serially diluted into DNA from a wild-type clone (WM3) to the following percentages: 0%, 0.1%, 0.5%, 1%, 5%, 10%, 20%, and 30%. Sensitivity to the L265P mutation by direct sequencing was 10% (Figure 1 D).
(A) Sequencing revealed a T to C transition resulting in a leucine to proline substitution at amino acid position 265 (WM5).
(B) Wild-type sequences (T) are shown as a control (WM2).
(C) Direct sequencing showed both wild-type and mutant alleles in WM5 and WM9, and the wild-type allele only in WM2.
(D) Sensitivity of direct sequencing. L265P-positive DNA (WM5) was diluted into wild-type DNA (WM3) before amplification. Aberrant bands were detected in samples containing 10% or more of the L265P mutation.
BSiE1 restriction enzyme digestion
Since the percentage of lymphocytes (median 27.3%, 13.5-96.4) in the bone marrow varied in each WM patient, the mutation may have been undetectable by direct sequencing in some cases. Thus we tested for the mutation with BSiE1 digestion. To determine sensitivity, DNA from the L265P-positive clone (WM5) was serially diluted into DNA from a wild-type clone (WM2 or WM3) to the following percentages: 0%, 0.1%, 0.5%, 1%, and 5%. Sensitivity to the L265P mutation was 0.1-0.5% in our study (Figure 2 A). To compare the sensitivity of direct sequencing with BSiE1 digestion, we used the same tube of PCR products for both analyses. We used the same tube of PCR products to screen for the mutation in other samples. The mutation was repeatedly confirmed with different tubes of PCR products. Aberrant bands corresponding to the mutation were detected in 21 of the 28 patients: 19 of the 25 WM (76%), one of the 2 non-IgM-secreting LPL, and B-cell lymphoma with IgG M-protein (Tables 1-2, Figure 2 B-D). All but one patient (WM21) with aberrant bands had hemizygous mutation (Table 2). Of the 21 patients with aberrant bands, 9 had the mutation detected by direct sequencing. Most patients with relatively strong bands were shown to have the mutation by direct sequencing. All of the 9 patients, in whom the L265P mutation was detected by direct sequencing, also showed the mutation by BSiE1 digestion (Table 2). To confirm these results, several samples without aberrant bands by digestion were also sequenced; however, only the wild-type sequences were obtained. We also examined in the 38 patients with myeloma with BSiE1 digestion; however, no aberrant bands were observed.
Ten μl of PCR products was digested with BSiE1, separated by electrophoresis through a 2% agarose gel, stained with ethidium bromide, and visualized by ultraviolet illumination. The size of the products is indicated on the left.
(A) Sensitivity of BSiE1 digestion. L265P-positive DNA (WM5) was diluted into wild-type DNA (WM3) before amplification. Aberrant bands were detected in samples containing 0.5% or more of the L265P mutation. Lane 1, 100 bp ladder; lane 2, 0%; lane 3, 0.1%; lane 4, 0.5%; lane 5, 1%; lane 6, 5%; lane 7, WM5.
(B) Aberrant bands were detected in 10 of 14 samples from WM patients (lanes 2, 5, 6, 8, 9, 10, 11, 12, 14, and 15). Lane 1, 100 bp ladder; lane 2, WM1; lane 3, WM2; lane 4, WM3; lane 5, WM4; lane 6, WM5; lane 7, WM6; lane 8, WM7; lane 9, WM8; lane 10, WM9; lane 11, WM10; lane 12, WM11; lane 13, WM12, lane 14, WM13; lane 15, WM14.
(C) Aberrant bands were detected in 8 of 9 samples from WM patients (lanes 2, 3, 4, 5, 6, 8, 9, and 10) and non-Hodgkin’s lymphoma patient (NHL3, lane 12). Lane 1, 100 bp ladder; lane 2, WM15; lane 3, WM16; lane 4, WM17; lane 5, WM18; lane 6, WM19; lane 7, WM20; lane 8, WM21; lane 9, WM22; lane 10, WM23; lane 11, NHL1; lane 12, NHL3; lane 13, normal lymphocyte 1; lane 14, water.
(D) Strength of aberrant bands varied in accordance with percentages of L265P-positive DNA. L265P-positive DNA (WM5) was diluted into wild-type DNA (WM3) before amplification. Lane 1, 100 bp ladder; lane 2, 50%; lane 3, 80%; lane 4, 90%; lane 5, 100%.
AS-PCR
Sensitivity to the L265P mutation by AS-PCR was 0.1-0.5% in our study (Figure 3 A). The mutation was detected in 20 of the 28 patients: 18 of the 25 WM (72%), one of the 2 non-IgM-secreting LPL, and B-cell lymphoma with IgG M-protein (Table 2, Figure 3 B-C). All of the 18 patients, in whom the L265P mutation was detected by AS-PCR, were also shown to have the mutation by BSiE1 digestion (Table 2).
Ten μl of PCR products was separated by electrophoresis through a 2% agarose gel, stained with ethidium bromide, and visualized by ultraviolet illumination. The size of the products is indicated on the left.
(A) Sensitivity of AS-PCR. L265P-positive DNA (WM5) was diluted into wild-type DNA (WM2) before amplification. Mutations were detected in samples containing 0.1% or more of the L265P mutation. Lane 1, 100 bp ladder; lane 2, 0%; lane 3, 0.1%; lane 4, 0.5%; lane 5, 1%; lane 6, 0%; lane 7, 0.1%; lane 8, 0.5%; lane 9, 1%.
(B) Aberrant bands were detected in 12 of 16 samples from WM patients (lanes 2, 5, 6, 8, 9, 10, 11, 12, 14, 15, 16, and 17). Lane 1, 100 bp ladder; lane 2, WM1; lane 3, WM2; lane 4, WM3; lane 5, WM4; lane 6, WM5; lane 7, WM6; lane 8, WM7; lane 9, WM8; lane 10, WM9; lane 11, WM10; lane 12, WM11; lane 13, WM12, lane 14, WM13; lane 15, WM14; lane 16, WM15; lane 17, WM16.
(C) Aberrant bands were detected in 6 of 10 samples from WM patients (lanes 2, 3, 6, 7, 8, and 10) and 2 of 3 non-Hodgkin’s lymphoma patients (lanes 12 and 13). Lane 1, 100 bp ladder; lane 2, WM17; lane 3, WM18; lane 4, WM19; lane 5, WM20; lane 6, WM21; lane 7, WM22; lane 8, WM23; lane 9, WM24; lane 10, WM25; lane 11, NHL1; lane 12, NHL2; lane 13, NHL3; lane 14, normal lymphocyte; lane 15, water.
The location of the analyzed mutation and a schema of the involved pathway are shown in Figure 4.
TIRAP, TIR domain containing adaptor protein; IRAK, IL-1 receptor-associated kinase; BTK, Bruton’s tyrosine kinase; TRAF, tumor necrosis factor receptor-associated factor; TAK, TGF-β-activated kinase; TAB, TAK binding protein; IκB, inhibitor κB; IKK, IκB kinase; NF-κB, nuclear factor-κB.
Statistical analysis
Analysis between WM and myeloma.
The incidence of the mutation by BSiE1 digestion was significantly higher in WM than in myeloma (p=1.3x10-10, odds ratio=∞) (Table 3).
| Incidence of mutation (%) | P-value | Odds ratio (95% CI) | |
|---|---|---|---|
| L265P mutation and type of disease* | |||
| WM versus myeloma | 19/25 (76) versus 0/38 (0) | 1.3x10-10† | ∞ |
| L265P mutation in WM* | |||
| Male versus female | 15/16 (94) versus 4/9 (44) | 1.2x10-2† | 18.75 (1.68-209.55) |
| κ chain versus λ chain | 15/18 (83) versus 4/7 (57) | 0.19 | 3.75 (0.54-26.19) |
| Incidence of mutation (%) | P-value | ||
| L265P mutation and methods in WM | |||
| BSiE1 digestion and direct sequencing | 19/25 (76) and 7/25 (28) | 5.3x10-4† | |
| BSiE1 digestion and AS-PCR | 19/25 (76) and 18/25 (72) | 0.32 | |
| P-value | |||
| Percentage of lymphocytes in WM | |||
| L265P group and wild-type group* | 0.49 | ||
| Male and female | 0.17 | ||
| IgM concentration and L265P mutation in WM | |||
| L265P group and wild-type group* | 0.09 |
Table 3. Statistical analysis for the L265P mutation.
Analysis using different genotyping methods in WM.
The L265P mutation was more frequently detected in the 25 WM patients, by BSiE1 digestion (76%) than by direct sequencing (28%) (p=5.3x10-4) (Table 3). No siginificant difference was observed in the incidence of the L265P mutation between BSiE1 digestion (76%) and AS-PCR (72%) (p=0.32).
Association between clinical characteristics and the L265P mutation by BSiE1 digestion in WM.
Detection of the L265P mutation by BSiE1 digestion was significantly more frequent in males (15/16, 94%) than in females (4/9, 44%) (p=1.2x10-2, odds ratio=18.75) (Table 3). The mutation was more frequent in the κ light chain group (15/18, 83%) than in the λ light chain group (4/7, 57%), but this was not significant (p=0.19, odds ratio=3.75). The percentage of lymphocytes was not significantly different between the L265P group and wild-type group (p=0.49). It was not significantly different between male and female patients (p=0.17). The IgM concentration was not significantly different between the L265P group and wild-type group (p=0.09).
Discussion
The L265P mutation of the MYD88 gene was detected by direct sequencing in 7 of the 25 patients with WM. It was detectable in 19 of the 25 WM patients by BSiE1 enzyme digestion and 18 of the 25 WM by AS-PCR. On the contrary, the L265P mutation was absent in the 38 myeloma patients. A recent study showed that the L265P mutation was found in 91% of WM patients but not in 10 myeloma patients [14]. Our results are consistent with this observation. In the present study, besides the patients with WM, 1 low grade B-cell lymphoma with IgG M-protein had the L265P mutation. Although a previous study showed an association between the mutation and IgM M-protein, our results demonstrated that the L265P mutation was also present in B-cell lymphoma with IgG M-protein [15].
The sensitivity of direct sequencing has been reported to be about 10-20% [19-22]. Sensitivity to the L265P mutation by direct sequencing was 10% in our study. DNA derived from lymphoma cells may be lower than detectable levels in some cases. However, although the mutation was undetectable by direct sequencing in 18 of the 25 WM patients, 9 of the 18 patients had more than 20% lymphocytes before mononuclear cell isolation. In most cases, the L265P mutation in WM was reported to be hemizygous [14]. Therefore direct sequencing can potentially detect the mutation in patients with more than 20% lymphocytes in their bone marrow before mononuclear cell isolation. On the other hand, the sensitivity of BSiE1 digestion and AS-PCR was 0.1-0.5% in our study, which indicated that these analyses were more sensitive methods. Although the patient with WM16 was administered prednisolone before sampling and had only 13.5% lymphocytes in her bone marrow, the mutation was detected by BSiE1 digestion and AS-PCR. To test the sensitivity of direct sequencing and BSiE1 digestion, we used the same tube of PCR products. Although a single clone was used as a sequencing template, Sanger sequencing sometimes showed a small peak in addition to a large peak at several nucleotides. Therefore, it was sometimes difficult to decide whether the wild-types of sequences or additional nucleotide changes were present. In contrast, it was easier to detect aberrant bands corresponding to the mutation using BSiE1 digestion, since wild- type DNA did not show aberrant bands.
The incidence of the L265P mutation detected by direct sequencing was lower in the 25 patients with WM than in the recent report [14]. Lymphocyte counts (the percentage of lymphocytes) include lymphoma cells as well as normal lymphocytes. Since the recent study used mononuclear cells sorted by magnetic beads [14], the mutation may have been more frequent than in the present study. In contrast, the proportion of lymphoma cells may have been lower than the detectable levels by direct sequencing in other cases in which the mutation was detected by BSiE1 digestion (WM1, WM4, WM8, WM10, WM13, WM14, WM16, WM18, WM19, WM22, WM23, and WM25). Another possibility is that a substantial proportion of lymphoma cells do not harbor the mutation in L265P-positive cases. WM5, which showed aberrant bands by BSiE1 digestion, contained 47.4% lymphocytes with lymphoplasmacytic morphology in the bone marrow before mononuclear cell isolation. The L265P mutation was detected by direct sequencing; however, the mutation was only found in two of the 9 clones from WM5. Moreover, although WM8 had aberrant bands by BSiE1 digestion and contained 85.6% lymphocytes in the bone marrow, the L265P mutation was not detected by direct sequencing.
Unexpectedly, the L265P mutation of WM was more frequent in males than in females. A larger percentage of lymphocytes in the bone marrow may have affect the incidence of the mutation; however, it was not significantly different between male and female patients. In addition, although tumor cells with the L265P mutation have growth and survival advantages due to NF-κB activation [13], the percentage of lymphocytes was not significantly different between the L265P group and wild-type group.
The IgM concentration was not significantly different between the L265P group and wild-type group (p=0.09). Although WM is an IgM-secreting-lymphoproliferative neoplasm, no minimal serum IgM level, nor a minimal percentage of bone marrow infiltration is required to establish a diagnosis. Large heterogeneity can exist among patients between their respective serum IgM levels and bone marrow involvement [3]. Moreover, the paraprotein concentration had no prognostic value in most studies, and does not appear to reflect disease bulk in individual patients [2].
The concentration of monoclonal IgM can vary widely in WM patients and it is impossible to define a concentration that reliably distinguishes WM from MGUS [1]. In the recent study, the L265P mutation was found in 2 of 21 patients with IgM MGUS (10%). One of the 2 patients had progressive disease with serial increases in serum IgM and decreases in hematocrit, while the disease was only recently diagnosed in the other patient [14]. This observation suggests that the L265P mutation is associated with the progression from IgM MGUS to WM. Recent studies further support this hypothesis [16,17]. In the present study, some of the patients also had a history of IgM MGUS. Unfortunately, we were unable to collect cells in their MGUS stage to establish the significance of the mutation in the disease progression.
In summary, this study showed that the L265P mutation was frequent in WM patients and absent in myeloma patients. Our results revealed that BSiE1 digestion and AS-PCR were more sensitive than direct sequencing. Since some patients only had a small amount of the mutant allele, the contribution of the mutation remains to be clarified in these cases. Further studies need to be conducted to elucidate the genesis and clinical significance of the L265P mutation in WM patients and develop new therapeutic approaches through the NF-κB signaling pathway.
Author Contributions
Conceived and designed the experiments: NM KY NT MS MT TM. Performed the experiments: NM M. Ohwashi M. Okada. Analyzed the data: NM KY KM TM. Contributed reagents/materials/analysis tools: NM M. Ohwashi KY NT MT TM. Wrote the manuscript: NM JT.
References
- 1. Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR et al. (2003) Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 30: 110-115. doi:https://doi.org/10.1053/sonc.2003.50082. PubMed: 12720118.
- 2. Johnson SA, Birchall J, Luckie C, Oscier DG, Owen RG (2006) Guidelines on the management of Waldenström macroglobulinaemia. Br J Haematol 132: 683–697. doi:https://doi.org/10.1111/j.1365-2141.2005.05948.x. PubMed: 16487169.
- 3. Treon SP (2009) How I treat Waldenström macroglobulinemia. Blood 114: 2375-2385. doi:https://doi.org/10.1182/blood-2009-05-174359. PubMed: 19617573.
- 4. Iwasaki A, Medzhitov R (2010) Regulation of adaptive immunity by the innate immune system. Science 327: 291-295. doi:https://doi.org/10.1126/science.1183021. PubMed: 20075244.
- 5. Watters TM, Kenny EF, O’Neill LA (2007) Structure, function and regulation of the Toll/IL-1 receptor adaptor proteins. Immunol Cell Biol 85: 411-419. doi:https://doi.org/10.1038/sj.icb.7100095. PubMed: 17667936.
- 6. Loiarro M, Gallo G, Fantò N, De Santis R, Carminati P et al. (2009) Identification of critical residues of the MyD88 death domain involved in the recruitment of downstream kinases. J Biol Chem 284: 28093-28103. doi:https://doi.org/10.1074/jbc.M109.004465. PubMed: 19679662.
- 7. Kawagoe T, Sato S, Matsushita K, Kato H, Matsui K et al. (2008) Sequential control of Toll-like receptor-dependent responses by IRAK1 and IRAK2. Nat Immunol 9: 684-691. doi:https://doi.org/10.1038/ni.1606. PubMed: 18438411.
- 8. Cohen L, Henzel WJ, Baeuerle PA (1998) IKAP is a scaffold protein of the IkappaB kinase complex. Nature 395: 292-296. doi:https://doi.org/10.1038/26254. PubMed: 9751059.
- 9. Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W et al. (2011) Oncogenically active MYD88 mutations in human lymphoma. Nature, 470: 115-119. doi:https://doi.org/10.1038/nature09671. PubMed: 21179087.
- 10. Lohr JG, Stojanov P, Lawrence MS, Auclair D, Chapuy B et al. (2012) Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U_S_A, 109: 3879-3884. doi:https://doi.org/10.1073/pnas.1121343109. PubMed: 22343534.
- 11. Yan Q, Huang Y, Watkins AJ, Kocialkowski S, Zeng N et al. (2012) BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas. Haematologica 97: 595-598. doi:https://doi.org/10.3324/haematol.2011.054080. PubMed: 22102703.
- 12. Li ZM, Rinaldi A, Cavalli A, Mensah AA, Ponzoni M et al. (2012) MYD88 somatic mutations in MALT lymphomas. Br J Haematol 158: 662-664. doi:https://doi.org/10.1111/j.1365-2141.2012.09176.x. PubMed: 22640364.
- 13. Leleu X, Eeckhoute J, Jia X, Roccaro AM, Moreau AS et al. (2008) Targeting NF-kappaB in Waldenstrom macroglobulinemia. Blood 111: 5068-5077. doi:https://doi.org/10.1182/blood-2007-09-115170. PubMed: 18334673.
- 14. Treon SP, Xu L, Yang G, Zhou Y, Liu X et al. (2012) MYD88 L265P somatic mutation in Waldenström’s macroglobulinemia. N Engl J Med 367: 826-833. doi:https://doi.org/10.1056/NEJMoa1200710. PubMed: 22931316.
- 15. Gachard N, Parrens M, Soubeyran I, Petit B, Marfak A et al. (2013) IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas. Leukemia 27: 183-189. doi:https://doi.org/10.1038/leu.2012.257. PubMed: 22944768.
- 16. Xu L, Hunter ZR, Yang G, Zhou Y, Cao Y et al. (2013) MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood 121: 2051-2058. doi:https://doi.org/10.1182/blood-2012-09-454355. PubMed: 23321251.
- 17. Varettoni M, Arcaini L, Zibellini S, Boveri E, Rattotti S et al. (2013) Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms. Blood 121: 2522-2528. doi:https://doi.org/10.1182/blood-2012-09-457101. PubMed: 23355535.
- 18. Mori N, Yokota J, Akiyama T, Sameshima Y, Okamoto A et al. (1990) Variable mutations of the RB gene in small-cell lung carcinoma. Oncogene 5: 1713-1717. PubMed: 2176283.
- 19. Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A et al. (2003) Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 102: 276-283. doi:https://doi.org/10.1182/blood-2002-09-2896. PubMed: 12623848.
- 20. James C, Delhommeau F, Marzac C, Teyssandier I, Le Coue´dic J-P et al. (2006) Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis. Leukemia 20: 350–353. doi:https://doi.org/10.1038/sj.leu.2404069. PubMed: 16341032.
- 21. Lasho TL, Pardanani A, McClure RF, Mesa RA, Levine RL et al. (2006) Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time. Br J Haematol 135: 683–687. doi:https://doi.org/10.1111/j.1365-2141.2006.06348.x. PubMed: 17107350.
- 22. Angulo B, García-García E, Martínez R, Suárez-Gauthier A, Conde E et al. (2010) A Commercial Real-Time PCR Kit Provides Greater Sensitivity than Direct Sequencing to Detect KRAS Mutations : A Morphology-Based Approach in Colorectal Carcinoma. J Mol Diagn 12: 292-299. doi:https://doi.org/10.2353/jmoldx.2010.090139. PubMed: 20203003.